Symbols / ACOG Stock $6.86 +0.07% Alpha Cognition Inc. Common Stock

Healthcare • Biotechnology • Canada • NCM
ACOG (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Michael E. McFadden B.B.A.
Exch · Country NCM · Canada
Market Cap 149.26M
Enterprise Value 83.21M
Income -20.67M
Sales 10.22M
FCF (ttm) -14.04M
Book/sh 2.87
Cash/sh 3.03
Employees —
Insider 10d —
IPO Nov 12, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -13.71
PEG —
P/S 14.60
P/B 2.39
P/C —
EV/EBITDA -3.68
EV/Sales 8.14
Quick Ratio 7.70
Current Ratio 8.65
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.18
EPS next Y -0.50
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-26
ROA -21.71%
ROE -40.68%
ROIC —
Gross Margin 81.26%
Oper. Margin -283.75%
Profit Margin -202.24%
Shs Outstand 21.77M
Shs Float 11.03M
Insider Own 9.79%
Instit Own 52.65%
Short Float 0.99%
Short Ratio 3.05
Short Interest 205.33K
52W High 11.54
vs 52W High -40.60%
52W Low 4.50
vs 52W Low 52.33%
Beta 2.52
Impl. Vol. —
Rel Volume 0.29
Avg Volume 67.69K
Volume 19.82K
Target (mean) $16.00
Tgt Median $16.00
Tgt Low $14.00
Tgt High $18.00
# Analysts 2
Recom Strong_buy
Prev Close $6.85
Price $6.86
Change 0.07%
About

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$16.00
Mean price target
2. Current target
$6.86
Latest analyst target
3. DCF / Fair value
$-11.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.86
Low
$14.00
High
$18.00
Mean
$16.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-17 init Craig-Hallum — → Buy $14
2025-12-19 reit HC Wainwright & Co. Buy → Buy $18
2025-10-20 main HC Wainwright & Co. Buy → Buy $18
2025-05-16 reit HC Wainwright & Co. Buy → Buy $20
2025-04-01 reit HC Wainwright & Co. Buy → Buy $20
2025-03-31 reit HC Wainwright & Co. Buy → Buy $20
News
RSS: Latest ACOG news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-10 Cawkell (Kenneth Anthony) Director of Issuer — 12,000 $0.02 $300
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
10.22
0.00
0.00
0.00
Operating Revenue
10.22
0.00
0.00
0.00
Cost Of Revenue
1.92
0.00
—
—
Reconciled Cost Of Revenue
1.92
0.00
—
—
Gross Profit
8.30
0.00
—
—
Operating Expense
30.88
+167.43%
11.55
+20.08%
9.62
-28.58%
13.47
Research And Development
1.87
-52.35%
3.92
-19.73%
4.88
-44.61%
8.82
Selling General And Administration
29.04
+262.50%
8.01
+63.16%
4.91
+21.29%
4.05
Selling And Marketing Expense
1.81
+1398.48%
0.12
+511.25%
0.02
-37.63%
0.03
General And Administrative Expense
27.23
+245.08%
7.89
+61.35%
4.89
+21.76%
4.02
Salaries And Wages
20.08
+748.47%
2.37
-30.71%
3.42
+29.90%
2.63
Other Gand A
7.14
+29.32%
5.52
+274.69%
1.47
+6.32%
1.39
Other Operating Expenses
-0.08
+82.52%
-0.46
-78.07%
-0.26
-151.09%
0.51
Total Expenses
32.80
+184.02%
11.55
+20.08%
9.62
-28.58%
13.47
Operating Income
-22.58
-95.52%
-11.55
-20.08%
-9.62
+28.58%
-13.47
Total Operating Income As Reported
-22.66
-88.64%
-12.01
-20.87%
-9.94
—
EBITDA
-22.52
-96.39%
-11.47
+15.69%
-13.60
-14.78%
-11.85
Normalized EBITDA
-22.61
-172.31%
-8.30
+12.85%
-9.53
+28.76%
-13.37
Reconciled Depreciation
0.06
-27.88%
0.08
-3.86%
0.08
-7.09%
0.09
EBIT
-22.58
-95.52%
-11.55
+15.62%
-13.69
-14.61%
-11.94
Total Unusual Items
0.09
+102.79%
-3.16
+22.35%
-4.08
-367.78%
1.52
Total Unusual Items Excluding Goodwill
0.09
+102.79%
-3.16
+22.35%
-4.08
-367.78%
1.52
Special Income Charges
—
-0.04
0.00
+100.00%
-0.01
Other Special Charges
—
—
0.02
—
Impairment Of Capital Assets
—
0.04
0.00
-100.00%
0.01
Restructuring And Mergern Acquisition
—
—
—
0.00
Net Income
-20.67
-39.77%
-14.79
-7.45%
-13.76
-13.61%
-12.11
Pretax Income
-20.67
-39.77%
-14.79
-7.45%
-13.76
-13.61%
-12.11
Net Non Operating Interest Income Expense
1.90
+1074.89%
0.16
+329.35%
-0.07
+58.77%
-0.17
Interest Expense Non Operating
—
0.19
+140.35%
0.08
-55.29%
0.17
Net Interest Income
1.90
+1074.89%
0.16
+329.35%
-0.07
+58.77%
-0.17
Interest Expense
—
0.19
+140.35%
0.08
-55.29%
0.17
Interest Income Non Operating
1.90
+1074.89%
0.16
+2276.01%
0.01
+253.45%
0.00
Interest Income
1.90
+1074.89%
0.16
+2276.01%
0.01
+253.45%
0.00
Other Income Expense
0.01
+100.30%
-3.40
+16.53%
-4.08
-367.78%
1.52
Other Non Operating Income Expenses
-0.08
+67.18%
-0.24
—
—
Gain On Sale Of Security
0.09
+102.79%
-3.16
+22.35%
-4.08
-366.82%
1.53
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-20.67
-39.77%
-14.79
-7.45%
-13.76
-13.61%
-12.11
Net Income From Continuing Operation Net Minority Interest
-20.67
-39.77%
-14.79
-7.45%
-13.76
-13.61%
-12.11
Net Income From Continuing And Discontinued Operation
-20.67
-39.77%
-14.79
-7.45%
-13.76
-13.61%
-12.11
Net Income Continuous Operations
-20.67
-39.77%
-14.79
-7.45%
-13.76
-13.61%
-12.11
Normalized Income
-20.76
-78.58%
-11.62
-19.98%
-9.69
+28.95%
-13.64
Net Income Common Stockholders
-20.67
-39.77%
-14.79
-7.45%
-13.76
-13.61%
-12.11
Diluted EPS
-1.17
+42.65%
-2.04
+46.87%
-3.84
+14.67%
-4.50
Basic EPS
-1.17
+42.65%
-2.04
+46.87%
-3.84
+14.67%
-4.50
Basic Average Shares
17.68
+143.94%
7.25
+102.15%
3.59
+31.87%
2.72
Diluted Average Shares
17.68
+143.94%
7.25
+102.15%
3.59
+31.87%
2.72
Diluted NI Availto Com Stockholders
-20.67
-39.77%
-14.79
-7.45%
-13.76
-13.61%
-12.11
Amortization
0.02
-73.03%
0.08
-3.04%
0.08
+0.00%
0.08
Amortization Of Intangibles Income Statement
0.02
-73.03%
0.08
-3.04%
0.08
+0.00%
0.08
Depreciation Amortization Depletion Income Statement
0.06
-27.88%
0.08
-3.86%
0.08
-7.09%
0.09
Depreciation And Amortization In Income Statement
0.06
-27.88%
0.08
-3.86%
0.08
-7.09%
0.09
Depreciation Income Statement
0.04
+2652.86%
0.00
-36.04%
0.00
-75.39%
0.01
Provision For Doubtful Accounts
—
0.06
0.00
—
Total Other Finance Cost
—
0.46
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
79.73
+57.14%
50.74
+1969.06%
2.45
-16.90%
2.95
Current Assets
79.01
+57.23%
50.25
+2519.38%
1.92
-17.76%
2.33
Cash Cash Equivalents And Short Term Investments
66.05
+36.05%
48.55
+3357.31%
1.40
-32.61%
2.08
Cash And Cash Equivalents
66.05
+36.05%
48.55
+3357.31%
1.40
-32.61%
2.08
Cash Financial
—
—
1.40
-32.61%
2.08
Receivables
4.44
+1651.47%
0.25
+60.82%
0.16
0.00
Accounts Receivable
4.24
0.00
—
—
Other Receivables
0.20
-20.08%
0.25
+153.33%
0.10
—
Loans Receivable
—
0.00
-100.00%
0.06
0.00
Inventory
5.12
+732.91%
0.62
0.00
—
Raw Materials
3.73
0.00
0.00
—
Work In Process
0.73
+17.94%
0.62
0.00
—
Finished Goods
0.67
0.00
—
—
Prepaid Assets
3.12
+281.15%
0.82
+207.40%
0.27
+6.92%
0.25
Current Deferred Assets
0.22
0.00
—
—
Restricted Cash
0.06
+226.77%
0.02
-80.23%
0.09
0.00
Other Current Assets
—
—
0.37
+47.09%
0.25
Total Non Current Assets
0.72
+48.21%
0.49
-8.99%
0.53
-13.67%
0.62
Net PPE
0.33
+1113.35%
0.03
+1473.33%
0.00
-54.99%
0.00
Gross PPE
0.33
+1113.35%
0.03
+118.89%
0.01
+223.48%
0.00
Accumulated Depreciation
—
-0.01
-12.63%
-0.01
—
Construction In Progress
—
0.02
0.00
—
Other Properties
0.33
+1113.35%
0.03
+118.89%
0.01
+223.48%
0.00
Goodwill And Other Intangible Assets
0.39
-5.22%
0.41
-22.38%
0.53
-13.41%
0.61
Other Intangible Assets
0.39
-5.22%
0.41
-22.38%
0.53
-13.41%
0.61
Other Non Current Assets
—
0.05
—
—
Total Liabilities Net Minority Interest
17.20
+47.74%
11.64
+62.69%
7.16
+67.54%
4.27
Current Liabilities
9.13
+172.48%
3.35
+28.09%
2.62
-35.52%
4.06
Payables And Accrued Expenses
8.98
+268.01%
2.44
+74.97%
1.39
-39.25%
2.29
Payables
3.07
+251.52%
0.87
+83.51%
0.48
-76.41%
2.02
Accounts Payable
3.07
+251.52%
0.87
+83.51%
0.48
-76.41%
2.02
Current Accrued Expenses
5.91
+277.20%
1.57
+70.55%
0.92
+229.63%
0.28
Pensionand Other Post Retirement Benefit Plans Current
—
—
0.79
+43.70%
0.55
Current Debt And Capital Lease Obligation
—
0.91
-24.76%
1.21
+0.00%
1.21
Current Debt
—
0.91
-24.76%
1.21
+0.00%
1.21
Other Current Borrowings
—
0.91
-24.76%
1.21
+0.00%
1.21
Current Deferred Liabilities
0.15
0.00
-100.00%
0.01
0.00
Current Deferred Revenue
0.15
0.00
-100.00%
0.01
0.00
Total Non Current Liabilities Net Minority Interest
8.07
-2.67%
8.29
+82.63%
4.54
+2018.62%
0.21
Non Current Deferred Liabilities
0.04
0.00
—
—
Non Current Deferred Revenue
0.04
0.00
—
—
Other Non Current Liabilities
0.05
-54.10%
0.10
+22.18%
0.08
+914.17%
0.01
Stockholders Equity
62.53
+59.94%
39.09
+931.15%
-4.70
-256.29%
-1.32
Common Stock Equity
62.53
+59.94%
39.09
+931.14%
-4.70
-256.30%
-1.32
Capital Stock
133.89
+35.07%
99.13
+149.31%
39.76
-1.24%
40.26
Common Stock
133.89
+35.07%
99.13
+149.31%
39.76
-1.24%
40.26
Preferred Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Share Issued
21.74
+35.72%
16.02
+238.80%
4.73
+73.78%
2.72
Ordinary Shares Number
21.74
+35.72%
16.02
+238.80%
4.73
+73.78%
2.72
Additional Paid In Capital
25.85
+56.59%
16.51
-4.52%
17.29
—
Retained Earnings
-97.11
-27.04%
-76.44
-23.99%
-61.65
-23.33%
-49.99
Gains Losses Not Affecting Retained Earnings
-0.10
+0.00%
-0.10
+0.00%
-0.10
-101.24%
8.41
Other Equity Adjustments
-0.10
+0.00%
-0.10
+0.00%
-0.10
-101.24%
8.41
Total Equity Gross Minority Interest
62.53
+59.94%
39.09
+931.15%
-4.70
-256.29%
-1.32
Total Capitalization
62.53
+59.94%
39.09
+931.15%
-4.70
-256.29%
-1.32
Working Capital
69.88
+49.00%
46.90
+6823.55%
-0.70
+59.54%
-1.72
Invested Capital
62.53
+56.30%
40.01
+1245.56%
-3.49
-3112.37%
-0.11
Total Debt
—
0.91
-24.76%
1.21
+0.00%
1.21
Net Tangible Assets
62.14
+60.64%
38.68
+838.81%
-5.24
-170.64%
-1.93
Tangible Book Value
62.14
+60.64%
38.68
+838.80%
-5.24
-170.64%
-1.93
Current Notes Payable
—
—
1.22
+0.74%
1.21
Derivative Product Liabilities
7.99
-2.46%
8.19
+83.78%
4.46
+2063.10%
0.21
Dueto Related Parties Current
—
—
—
—
Preferred Stock Equity
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-20.38
-162.78%
-7.76
+11.86%
-8.80
+4.78%
-9.24
Cash Flow From Continuing Operating Activities
-20.38
-162.78%
-7.76
+11.86%
-8.80
+4.78%
-9.24
Net Income From Continuing Operations
-20.67
-39.77%
-14.79
-7.45%
-13.76
-13.61%
-12.11
Depreciation Amortization Depletion
0.06
-27.88%
0.08
-3.86%
0.08
-7.09%
0.09
Depreciation
—
—
0.00
-75.39%
0.01
Amortization Cash Flow
—
—
0.08
+0.00%
0.08
Depreciation And Amortization
0.06
-27.88%
0.08
-3.86%
0.08
-7.09%
0.09
Amortization Of Intangibles
—
—
0.08
+0.00%
0.08
Other Non Cash Items
-0.00
-100.09%
2.80
+41811.28%
-0.01
-104.00%
0.17
Stock Based Compensation
4.92
+334.98%
1.13
-52.24%
2.37
+39.24%
1.70
Provisionand Write Offof Assets
0.00
-100.00%
0.06
0.00
—
Asset Impairment Charge
0.00
-100.00%
0.04
0.00
-100.00%
0.01
Operating Gains Losses
-0.07
-102.22%
3.16
-22.53%
4.09
+324.04%
-1.82
Gain Loss On Investment Securities
-0.09
-102.79%
3.16
-22.53%
4.09
+324.04%
-1.82
Gain Loss On Sale Of PPE
0.02
0.00
—
—
Change In Working Capital
-4.62
-1811.16%
-0.24
+84.59%
-1.57
-157.45%
2.73
Change In Receivables
-4.24
0.00
—
—
Changes In Account Receivables
-4.24
0.00
—
—
Change In Inventory
-4.51
-632.91%
-0.62
0.00
—
Change In Prepaid Assets
-2.49
-270.81%
-0.67
-472.79%
-0.12
-118.92%
0.62
Change In Payables And Accrued Expense
6.52
+523.90%
1.05
+172.02%
-1.45
-168.77%
2.11
Change In Payable
6.52
+523.90%
1.05
+172.02%
-1.45
-168.77%
2.11
Change In Account Payable
6.52
+523.90%
1.05
+172.02%
-1.45
-168.77%
2.11
Change In Other Working Capital
0.10
—
—
—
Investing Cash Flow
-0.29
-999.17%
-0.03
0.00
+100.00%
-0.00
Cash Flow From Continuing Investing Activities
-0.29
-999.17%
-0.03
0.00
+100.00%
-0.00
Net PPE Purchase And Sale
-0.29
-999.17%
-0.03
0.00
+100.00%
-0.00
Purchase Of PPE
-0.29
-999.17%
-0.03
0.00
+100.00%
-0.00
Capital Expenditure
-0.29
-999.17%
-0.03
—
-0.00
Net Business Purchase And Sale
—
—
—
0.00
Net Intangibles Purchase And Sale
—
—
—
0.00
Purchase Of Intangibles
—
—
—
0.00
Financing Cash Flow
38.21
-30.33%
54.85
+566.49%
8.23
+33105.63%
0.02
Cash Flow From Continuing Financing Activities
38.21
-30.33%
54.85
+566.49%
8.23
+33105.63%
0.02
Net Issuance Payments Of Debt
-0.91
-121.47%
4.25
+7818.18%
-0.06
0.00
Issuance Of Debt
0.00
-100.00%
4.54
0.00
—
Repayment Of Debt
-0.91
-203.82%
-0.30
-445.45%
-0.06
0.00
Long Term Debt Issuance
0.00
-100.00%
4.54
0.00
—
Long Term Debt Payments
-0.91
-203.82%
-0.30
-445.45%
-0.06
0.00
Net Long Term Debt Issuance
-0.91
-121.47%
4.25
+7818.18%
-0.06
0.00
Net Common Stock Issuance
34.32
-39.30%
56.54
+513.01%
9.22
0.00
Cash Dividends Paid
—
—
0.00
0.00
Proceeds From Stock Option Exercised
7.31
+2322.51%
0.30
+1017.78%
0.03
-33.80%
0.04
Net Other Financing Charges
-2.51
+59.80%
-6.24
-545.87%
-0.97
—
Changes In Cash
17.54
-62.73%
47.07
+8364.33%
-0.57
+93.82%
-9.22
Effect Of Exchange Rate Changes
—
0.00
+100.00%
-0.02
-637.13%
0.00
Beginning Cash Position
48.56
+3149.36%
1.49
-28.27%
2.08
-81.56%
11.30
End Cash Position
66.11
+36.12%
48.56
+3149.36%
1.49
-28.27%
2.08
Free Cash Flow
-20.67
-165.65%
-7.78
+11.56%
-8.80
+4.83%
-9.25
Interest Paid Supplemental Data
0.00
-87.04%
0.04
-36.84%
0.06
+273.61%
0.02
Income Tax Paid Supplemental Data
—
—
0.00
0.00
Change In Income Tax Payable
—
—
—
—
Change In Tax Payable
—
—
—
—
Common Stock Issuance
34.32
-39.30%
56.54
+513.01%
9.22
0.00
Interest Paid CFF
—
—
-0.07
-342.36%
-0.02
Issuance Of Capital Stock
34.32
-39.30%
56.54
+513.01%
9.22
0.00
Sale Of Business
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category